Vasculitis Pathogenesis: Can We Talk About Precision Medicine?


Creative Commons License

ÖZEN S., Batu E. D.

FRONTIERS IN IMMUNOLOGY, cilt.9, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 9
  • Basım Tarihi: 2018
  • Doi Numarası: 10.3389/fimmu.2018.01892
  • Dergi Adı: FRONTIERS IN IMMUNOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: systemic vasculitis, genome-wide association studies, monogenic vasculitis, biomarker, precision medicine, GENOME-WIDE ASSOCIATION, HENOCH-SCHONLEIN PURPURA, FAMILIAL MEDITERRANEAN FEVER, INTRAVENOUS IMMUNOGLOBULIN THERAPY, ADENOSINE-DEAMINASE 2, BEHCETS-DISEASE, SUSCEPTIBILITY LOCI, TAKAYASU ARTERITIS, KAWASAKI-DISEASE, POLYARTERITIS-NODOSA
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Precision medicine is designing the medical care by taking into account the individual variability for each person. We have tried to address whether the existing data may guide precision medicine in primary systemic vasculitides (PSV). We have reviewed genome-wide association studies (GWAS) data, lessons from monogenic mimics of these diseases, and biomarker studies in immunoglobulin A vasculitis/Henoch-Schonlein purpura, Kawasaki disease, anti-neutrophil cytoplasmic antibody-associated vasculitis, polyarteritis nodosa (PAN), Takayasu arteritis, and Behcet's disease (BD). GWAS provide insights about the pathogenesis of PSV while whole exome sequencing studies lead to discovery of monogenic vasculitides, phenotype of which could mimic other types of vasculitis such as PAN and BD. Monogenic vasculitides form a subgroup of vasculitis which are caused by single gene alterations and discovery of these diseases has enabled more specific therapies in these patients. With increasing number of studies on biomarkers, new targets for treatment appear and better and structured follow-up of PSV patients will become possible. Proteomics and metabolomics studies are required to better categorize our patients with PSV so that we can manage them appropriately and offer more targeted therapy.